Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Ahead Of Patent Loss, Takeda’s Actos Benefits From Avandia Drop Off

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceutical's diabetes treatment Actos registered stronger-than-expected sales in the April-September period, benefiting from a price increase in the U.S. and the restricted use or market withdrawal of competitor Avandia

You may also be interested in...



Another Setback For Glitazones: Germany Withdraws Reimbursement For The Diabetes Drugs

Federal joint committee decision means GSK's Avandia and Takeda's Actos no longer will be reimbursed in Germany other than in exceptional cases.

Another Setback For Glitazones: Germany Withdraws Reimbursement For The Diabetes Drugs

Federal joint committee decision means GSK's Avandia and Takeda's Actos no longer will be reimbursed in Germany other than in exceptional cases.

GSK Will End Avandia Promotion Worldwide

Even in countries where the drug will still be sold, the firm projects "minimal" sales.

Table

View full table

Related Content

Scrip
Tags:
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC073682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By